Category Archives: – Biotech

Are the so-called mRNA vaccines actually nano-particles?

Diagram from “Speeding COVID-19 Drug Discovery with Quantum Dots”, Posted on November 5th, 2020 by Dr. Francis Collins March 16, 2023- by Steven E. Greer, MD

Posted in - Biotech, - Pharma, CDC, FDA, Infectious disease | Leave a comment

Vaccines no longer work. Period.

November 5, 2021- by Steven E. Greer, MD In the most prestigious journal in all of science, Science magazine posted this article. The authors studied vaccine efficacy over time in VA patients. The effectiveness at preventing COVID infections fell to … Continue reading

Posted in - Biotech, - Opinion, - Pharma, - Policy | Leave a comment

FDA CDER Director on Benlysta for lupus and adaptive clinical trials.

July 27, 2011- Janet Woodcock, MD, Director of the FDAs new drug division, CDER, discusses with Steven Greer,

Posted in - Biotech, - Pharma, FDA, Rheumatology | Leave a comment

Steven E. Greer, MD on OANN discussing virus therapies

April 16, 2020

Posted in - Biotech, - Generics, - Opinion, - Pharma, CDC, CMS, Congress, Emergency medicine, FDA, Geriatrics, Infectious disease, Internal Medicine, NIH, Pediatrics, Primary care medicine, Pulmonology, VA | Leave a comment

The FDA pathway for biosimilar drug approvals

March 26, 2015- Interviewed by Steven E. Greer,

Posted in - Biotech, - Generics, FDA | Leave a comment

New York Times: Booster shots cause immune system fatigue

December 30, 2021- by Steven E. Greer, MD Einstein’s definition of insanity, to paraphrase, is doing the same thing over and over and expecting different results.

Posted in - Biotech, - NEJM, - Opinion, - Pharma | Leave a comment

How to beat the virus with early treatment

July 22, 2021- by Steven E. Greer, MD I woke up yesterday with a slight malaise and I sneezed once. I knew I had come down with a virus

Posted in - Biotech, - Generics, - Opinion, - Pharma, - Policy, Duke, Emergency medicine, Geriatrics, Infectious disease, Internal Medicine, Pediatrics, Primary care medicine, Pulmonology | Leave a comment

The only thing we have to fear…is fear itself

March 13, 2020- by Steven E. Greer, MD Holy cow. The PGA Tour cancelled the Players Championship due to fears over the coronavirus.

Posted in - Biotech, - Medical Devices, - Opinion, - Pharma, - Policy, CDC, CMS, Congress, Emergency medicine, FDA, Infectious disease, Internal Medicine, NIH, Primary care medicine, Pulmonology, VA | Leave a comment

Florida becomes the first state to recommend against getting the gene therapy “vaccines” for COVID

October 9, 2022- by Steven E. Greer, MD

Posted in - Biotech, - Opinion, - Pharma, - Policy, Cardiology, CDC, FDA, Harvard, Infectious disease, Internal Medicine, Pediatrics, Primary care medicine | Leave a comment

Pfizer documents show vaccine causes high fetal death rates

February 3, 2022- by Steven E. Greer, MD

Posted in - Biotech, - Pharma, FDA, Infectious disease, Internal Medicine, NIH, Obstetrics and Gynecology, Pediatrics | Leave a comment

India, Mexico, and El Salvador distribute ivermectin to citizens in free COVID kits

January 20, 2022- by Steven E. Greer, MD As all hospitals in the U.S. refuse to administer lifesaving early treatments for the SARS-CoV-2 coronavirus,

Posted in - Biotech, - Generics, - Medical Devices, - Pharma, - Policy, Infectious disease, Internal Medicine | Leave a comment

What you need to know about the SARS-CoV-2 coronavirus vaccines

Update March 22, 2021- by Steven E. Greer, MD Tucker Carlson interviewed a surgeon who stated what I have known for many months. The signal

Posted in - Biotech, - Opinion, - Pharma, - Policy, CDC, Congress, FDA, Infectious disease, Internal Medicine, NIH | Leave a comment

Sen. Ron Johnson on the need for early treatment of the Wuhan coronavirus

December 13, 2020- by Steven E. Greer, MD This is straight from my book, Tony’s Virus, chapters 8 and chapter 10.

Posted in - Biotech, - Generics, - Opinion, - Pharma, - Policy, CDC, CMS, Congress, FDA, NIH | Leave a comment

The “surge in new Wuhan virus cases” is great news

June 26, 2020- by Steven E. Greer, MD I called it, once again. On June 9th, I wrote, “This unprecedented communist-party-like anarchy in

Posted in - Biotech, - Opinion, - Pharma, - Policy, Emergency medicine, Infectious disease, Internal Medicine, Pediatrics, Primary care medicine, Pulmonology | 2 Comments

Joe Piscopo interviews Steven E. Greer, MD: 5-22-2020

May 22, 2020

Posted in - Biotech, - Generics, - Opinion, - Pharma, - Policy, Emergency medicine, Infectious disease, Pulmonology | Leave a comment

Are there any medications to treat coronavirus?

(Also: How infectious and lethal is this Coronavirus COVID-19 compared to regular “flu”?) February 27, 2020- by Steven E. Greer, MD Gilead makes a not-yet-approved antiviral drug called remdisivir and it is being tested right

Posted in - Biotech, - Opinion, - Pharma, - Policy, CDC, Congress, FDA, Geriatrics, Infectious disease, Internal Medicine, NIH, Primary care medicine | 2 Comments

60 Minutes creates another publicist-paid puff-piece for an unethical medical researcher

December 8, 2019- by Steven E. Greer, MD CBS’ 60 Minutes featured an extremely unethical PhD medical researcher at Harvard named George

Posted in - Biotech, - Opinion, - Pharma, - Policy, CDC, Congress, FDA, Genetics, NIH | Leave a comment

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

February 27, 2017- interviewed by Steven E. Greer, MD We interviewed Joaquim Bellmunt, MD, PhD, the Director of the Bladder Cancer Center at Dana-Farber,

Posted in - Biotech, - NEJM, - Pharma, Harvard, Oncology | Leave a comment

Preventing HIV infection

July 28, 2014- Interviewed by Steven E. Greer, MD Rajesh Tim Gandhi, MD of the Massachusetts General Hospital discusses the NEJM review paper he co-wrote

Posted in - Biotech, - NEJM, - Pharma, General surgery, Harvard, Infectious disease, Primary care medicine | Leave a comment

Paul Richardson, MD: Current Therapies for Multiple Myeloma

December 15, 2015- Interviewed by Steven Greer, MD Dr. Paul Richardson, Clinical Director of the Multiple Myeloma Center at Harvard’s Dana-Farber

Posted in - Biotech, - Pharma, Harvard, Oncology | Leave a comment